Advances in immune checkpoint inhibitors for hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the fifth most common cancer, and the second leading cause of cancer-related death worldwide. Although recent advances in immune checkpoint inhibitor-based immunotherapy have initiated a new era for advanced HCC treatment, the majority of HCC patients receiving immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ji Won, Park, Su-Hyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Liver Cancer Association 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035682/
https://www.ncbi.nlm.nih.gov/pubmed/37383085
http://dx.doi.org/10.17998/jlc.2021.09.24

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035682/
https://www.ncbi.nlm.nih.gov/pubmed/37383085
http://dx.doi.org/10.17998/jlc.2021.09.24

Ejemplares similares